Vaccine Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Dermatitis Therapy
Study data from Mie University, Department of Dermatology provide new insights into dermatitis therapy
June 17th, 2009
Scientists discuss in 'IL-4/IL-13 antagonist DNA vaccination successfully suppresses Th2 type chronic dermatitis' new findings in dermatitis. According to recent research from Tsu, Japan, "Atopic dermatitis (AD) is a chronic disease with a Th2-type-cytokine dominant profile. Several cytokines and related peptides have been used for the treatment of AD but they were ineffective because of their limited biological half-life." "We have recently developed a highly efficient mouse dominant negative interleukin (IL)-4/IL-13 antagonist (IL-4DM), which blocks both IL-4 and IL-13 signal transductions. To examine the effects of IL-4DM in vivo in an AD model induced by the...
Source: Vaccine Weekly (2009-06-17)
|
